MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Phosphorylated peptides presented by MHC molecules represent a new class of neoantigens expressed on cancer cells and recognized by CD8 T-cells. These peptides are promising targets for cancer immunotherapy. Previous work identified an HLA-A*0201-restricted phosphopeptide from insulin receptor substrate 2 (pIRS2) as one such target. The purpose of this study was to characterize a second phosphopeptide, from breast cancer antiestrogen resistance 3 (BCAR3), and to evaluate safety and immunogenicity of a novel immunotherapic vaccine comprising either or both of these phosphorylated peptides. Methods: Phosphorylated BCAR3 protein was evaluated in melanoma and breast cancer cell lines by Western blot, and recognition by T-cells specific for HLA-A*0201-restricted phosphorylated BCAR3 peptide (pBCAR3 126-134) was determined by 51 Cr release assay and intracellular cytokine staining. Human tumor explants were also evaluated by mass spectrometry for presentation of pIRS2 and pBCAR3 peptides. For the clinical trial, participants with resected stage IIA–IV melanoma were vaccinated 6 times over 12 weeks with one or both peptides in incomplete Freund’s adjuvant and Hiltonol (poly-ICLC). Adverse events (AEs) were coded based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V.4.03, with provision for early study termination if dose-limiting toxicity (DLT) rates exceeded 33%. The enrollment target was 12 participants evaluable for immune response to each peptide. T-cell responses were assessed by interferon-γ ELISpot assay. Results: pBCAR3 peptides were immunogenic in vivo in mice, and in vitro in normal human donors, and T-cells specific for pBCAR3 126-134 controlled outgrowth of a tumor xenograft. The pIRS2 1097-1105 peptide was identified by mass spectrometry from human hepatocellular carcinoma tumors. In the clinical trial, 15 participants were enrolled. All had grade 1 or 2 treatment-related AEs, but there were no grade 3–4 AEs, DLTs or deaths on study. T-cell responses were induced to the pIRS2 1097-1105 peptide in 5/12 patients (42%, 90% CI 18% to 68%) and to the pBCAR3 126-134 peptide in 2/12 patients (17%, 90% CI 3% to 44%). Conclusion: This study supports the safety and immunogenicity of vaccines containing the cancer-associated phosphopeptides pBCAR3 126-134 and pIRS2 1097-1105, and the data support continued development of immune therapy targeting phosphopeptides. Future studies will define ways to further enhance the magnitude and durability of phosphopeptide-specific immune responses. Trial registration number: NCT01846143
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Proteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594
Zarling, A. L., Ficarro, S. B., White, F. M., Shabanowitz, J., Hunt, D. F., & Engelhard, V. H. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1755 · Cited by 213
Self-citationMohammed, F., Cobbold, M., Zarling, A. L., Salim, M., Barrett-Wilt, G. A., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., & Willcox, B. E. (2008) · Nature Immunology · doi:10.1038/ni.1660 · Cited by 155
Self-citation
Cited by
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
Metadata
- Authors
- Engelhard, V. H., Obeng, R. C., Cummings, K. L., Petroni, G. R., Ambakhutwala, A. L., Chianese-Bullock, K. A., Smith, K. T., Lulu, A., Varhegyi, N., Smolkin, M. E., Myers, P., Mahoney, K. E., Shabanowitz, J., Buettner, N., Hall, E. H., Haden, K., Cobbold, M., Hunt, D. F., Weiss, G., Gaughan, E., & Slingluff, Jr.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-05
- Volume
- 8
- Issue
- 1
- Pages
- e000262
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W3022287679
- Cited by
- 85
- References
- 7
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. https://app.cochat.ai/papers/10.1136/jitc-2019-000262
- The paper
- Engelhard, V. H., Obeng, R. C., Cummings, K. L., Petroni, G. R., Ambakhutwala, A. L., Chianese-Bullock, K. A., Smith, K. T., Lulu, A., Varhegyi, N., Smolkin, M. E., Myers, P., Mahoney, K. E., Shabanowitz, J., Buettner, N., Hall, E. H., Haden, K., Cobbold, M., Hunt, D. F., Weiss, G., . . . Slingluff, Jr. (2020). MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2019-000262
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.